Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234775 · ClinicalTrials.gov registry record · Phase 3
Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product
A Phase 3 study, sponsored by LIB Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT05234775 is a Phase 3 study that has completed, run by LIB Therapeutics. The registered enrollment target is 22 participants.
The verdict
NCT05234775, a Phase 3 study, has completed, sponsored by LIB Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
To compare the pharmacokinetics (PK), and pharmacodynamics (PD) of single subcutaneous (SC) doses of 300 mg LIB003 Process 1 (P1) and Process 2 (P2) drug product in subjects with or without statin therapy
Interventions
- DRUG lerodalcibep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2022-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05234775
The ClinicalTrials.gov registry entry for NCT05234775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LIB Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lerodalcibep is the first listed.
NCT05234775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05234775 about?
NCT05234775 is a clinical study titled "Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product". To compare the pharmacokinetics (PK), and pharmacodynamics (PD) of single subcutaneous (SC) doses of 300 mg LIB003 Process 1 (P1) and Process 2 (P2) drug product in subjects with or without statin therapy
What is the current status of trial NCT05234775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2022-01-28. Estimated completion is 2022-07-11.
What interventions are being tested in trial NCT05234775?
The interventions under investigation include: lerodalcibep (DRUG).
Who is sponsoring clinical trial NCT05234775?
This trial is sponsored by LIB Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.